TxCell Share Price

Stocks

TXCL

FR0010127662

Biotechnology & Medical Research

Real-time 5-day change 1st Jan Change
- EUR -.--% Intraday chart for TxCell -.--% +67.53%
Manager TitleAgeSince
Chief Operating Officer 50 -
Corporate Officer/Principal - -
Corporate Officer/Principal - -
Director TitleAgeSince
Chairman - 12/02/2019
Change 5-day change 1-year change 3-year change Capi.($)
-.--%-.--% - - 0
+4.16%+3.04%+49.37%+94.17% 7.42TCr
-3.11%-3.53%+20.19%+79.01% 5.74TCr
+0.89%-0.63%+2.17%+35.99% 4.76TCr
+0.36%+0.81%+342.39%+748.97% 4.43TCr
-0.96%-4.50%+24.96%+31.45% 4.25TCr
-0.20%-0.77%+4.13%+111.69% 4.07TCr
-0.54%+2.93%+9.31%+54.06% 3.1TCr
+1.92%+4.03%+32.26%+29.49% 2.85TCr
+0.05%-1.64%-8.14%-12.10% 2.43TCr
Average +0.25%-0.59%+52.96%+130.30% 4.34TCr
Weighted average by Cap. +0.45%-0.84%+57.17%+139.58%
Logo TxCell
TxCell is a biotechnology company which develops platforms for innovative customized cell immunotherapies from regulatory T cells (Treg) for the treatment of severe chronic inflammatory, autoimmune diseases and transplant rejection. TxCell is developing a platform for genetically modified T-cells, the CAR-Tregs. TxCell plans to release preclinical proof-of-concept data in 2017 and start a first clinical study by the end of 2018.
Employees
-
  1. Stock Market
  2. Stocks
  3. TXCL Stock